Drugmaker Aquestive Hit With Suit Over FDA Approval Delay
By Sydney Price · March 5, 2026, 9:31 PM EST
Pharmaceutical company Aquestive Therapeutics Inc. has been hit with a proposed class action accusing it of harming investors by failing to disclose the likelihood that the U.S. Food and Drug Administration...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login